PL EN


Preferences help
enabled [disable] Abstract
Number of results
2015 | 42 | 2 | 181-194
Article title

Ocena zmian stężenia leptyny i greliny, parametrów antropometrycznych oraz laboratoryjnych przed i po implantacji balonu żołądkowego

Content
Title variants
EN
Assessment of changes in leptin and ghrelin levels, anthropometric and laboratory parameters before and after implantation of the gastric balloon
Languages of publication
PL
Abstracts
EN
Introduction: Obesity is a syndrome characterized by weight gain over optimal weight which affects both adults and children. The aim of the study was to search for the relation between anthropometric parameters, lipid parameters, glucose, leptin and ghrelin concentrations in patients before and after the implantation of balloon–type gastric BIB (ORBERA). Material and methods: The material for the study was the whole blood derived from 45 people, including 35 women and 10 men voluntarily undergoing gastric balloon implantation. The concentration of glucose, total cholesterol, HDL and LDL, triglycerides, glucose, leptin and ghrelin were measured both before the implantation of the gastric balloon and after its removal. Simultaneously, the evaluation of anthropometric parameters such as body mass index (BMI), body fat distribution (WHR),% body fat and the excess weight loss/weight loss ratio EWL/WL) was done. Results: The statistical analysis showed a significant change of all measured parameters after gastric balloon implantation. There was a statistically significant decrease in variables such as body mass index (BMI), waist–to–hip ratio (WHR), % of body fat, excess weight loss/weight loss (ELW/WL), blood the concentration of glucose, cholesterol (total and LDL), triglycerides and leptin. Concentrations of HDL cholesterol and ghrelin increased significantly. Conclusion: The implantation of a balloon–type gastric BIB (ORBERA) has a beneficial effect on lipid parameters, glucose, leptin and ghrelin concentration. Moreover, it is connected with an the improvement of studied anthropometric parameters.
PL
Wstęp: Otyłość jest zespołem chorobowym cechującym się m.in. zwiększeniem masy ciała powyżej wartości optymalnej i dotyczy zarówno osób dorosłych, jak i dzieci. Celem pracy było poszukiwanie zależności między wskaźnikami antropometrycznymi, parametrami lipidogramu, stężeniami glukozy, leptyny oraz greliny u osób przed i po implantacji balonu żołądkowego typu BIB (ORBERA). Materiały i metody: Materiał do badania stanowiła krew pełna pochodząca od 45 osób, w tym 35 kobiet i 10 mężczyzn, dobrowolnie poddających się implantacji balonu żołądkowego. Zbadano stężenie glukozy, cholesterolu całkowitego, frakcji HDL i LDL, triglicerydów oraz stężenie leptyny i greliny oraz dokonano oceny parametrów antropometrycznych: wskaźnika masy ciała (BMI), wskaźnika dystrybucji tkanki tłuszczowej (WHR), % tkanki tłuszczowej oraz wskaźnika EWL/WL (ang. excess weight loss/weight loss) zarówno przed implantacją balonu żołądkowego, jak i po jego usunięciu. Wyniki: Analiza statystyczna wykazała istotną zmianę wszystkich mierzonych parametrów po implantacji balonu żołądkowego. Stwierdzono statystycznie istotny spadek wartości takich zmiennych, jak: BMI, WHR, % tkanki tłuszczowej, ELW/WL, stężenie glukozy, cholesterolu, triglicerydów, cholesterolu frakcji LDL i leptyny. Wartości stężenia cholesterolu frakcji HDL i greliny istotnie wzrosły. Wnioski: Zabieg implantacji balonu żołądkowego typu BIB (ORBERA) wpływa korzystnie na parametry gospodarki lipidowej, stężenia glukozy, greliny i leptyny, jak również wiąże się z poprawą badanych parametrów antropometrycznych.
Discipline
Year
Volume
42
Issue
2
Pages
181-194
Physical description
References
  • Nikolopoulos D, Theocharis S, Kouraklis G. Ghrelin, another factor affecting bone metabolism. Med Sci Monit. 2010; 16: 147–162.
  • Kocełak P, Zahorska–Markiewicz B, Olszanecka–Glinianowicz M. Hormonal regulation of feeding. Endokrynol Pol. 2009; 60: 296–301.
  • Suzuki K, Simpson KA, Minnion JS, Shillito JC, Bloom SR. The role of gut hormones and the hypothalamus in appetite regulation. Endocr J. 2010; 57: 359–372.
  • Januszewicz W, Kokot F. Zaburzenia przemiany materii. „Interna” PZWL 2006; 1609–1615
  • Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med. 1999; 130: 671–680.
  • Baskin DG, Breininger JF, Schwartz MW. Leptin receptor mRNA identifies a subpopulation of neuropeptide Y neurons activated by fasting in rat hypothalamus. Diabetes. 1999; 48: 828 –833.
  • Kojima M, Kangawa K. Ghrelin: more than endogenous growth hormone secretagogue. Ann N Y Acad Sci. 2010; 1200: 140–148.
  • Asakawa A, Inui A, Kaga O, Yuzuriha H, Nagata T, Ueno N i wsp. Ghrelin is an appetite–stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 2001; 120: 337–345.
  • Barazzoni R, Zanetti M, Stebel M, Biolo G, Cattin L, Guarnieri G. Hyperleptinemia prevents increased plasma ghrelin concentration during short–term moderate caloric restriction in rats. Gastroenterology. 2003; 124: 1188–1192.
  • Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001; 50: 707–709.
  • Schaller G, Schmidt A, Pleiner J, Woloszczuk W, Wolzt M, Luger A. Plasma ghrelin concentrations are not regulated by glucose or insulin: a double–blind, placebo–controlled crossover clamp study. Diabetes. 2003; 52: 16–20.
  • McLaughlin T, Abbasi F, Lamendola C, Frayo RS, Cummings DE. Plasma ghrelin concentrations are decreased in insulin–resistant obese adults relative to equally obese insulin–sensitive controls. J Clin Endocrinol Metab. 2004; 89: 1630–1635.
  • Goldstone AP, Thomas EL, Brynes AE, Castroman G, Edwards R, Ghatei MA i wsp. Elevated fasting plasma ghrelin in prader–willi syndrome adults is not solely explained by their reduced visceral adiposity and insulin resistance. J Clin Endocrinol Metab. 2004; 89: 1718–1726.
  • Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem. 2004; 50: 1511–1525.
  • Koziołkiewicz M. Koncepcja nutrigenomiki. Biotechnologia 2009; 4: 9–34.
  • Engeli S, Böhnke J, Feldpausch M, Gorzelniak K, Janke J, Bátkai S i wsp. Activation of the Peripheral Endocannabinoid System in Human Obesity Diabetes. 2005; 54: 2838–2843.
  • Hosoda H, Kojima M, Matsuo H, Kangawa K. Ghrelin and Des–acyl Ghrelin: Two Major Forms of Rat Ghrelin Peptide in Gastrointestinal Tissue Biochemical and Biophysical Research Communications 2000; 279: 909–913.
  • Yang J, Zhao TJ, Goldstein JL, Brown MS. Inhibition of ghrelin O–acyltransferase (GOAT) by octanoylated pentapeptides. Proc Natl Acad Sci 2008; 105: 10750–10755.
  • Castañeda TR, Tong J, Datta R, Culler M, Tschöp MH. Ghrelin in the regulation of body weight and metabolism. Front Neuroendocrinol. 2010; 31: 44–60.
  • Murawska S Czerwonka–Szaflarska M. Meaning of ghrelin and leptin in gastrointestinal tract diseases. Pol Merkuriusz Lekarski 2010; 28: 75–78.
  • Granata R, Baragli A, Settanni F, Scarlatti F, Ghigo E. Unraveling the role of the ghrelin gene peptides in the endocrine pancreas. J Mol Endocrinol. 2010; 45: 107–118.
  • Nikolopoulos D, Theocharis S, Kouraklis G. Ghrelin: a potential therapeutic target for cancer. Regul Pept. 2010;163: 7–17.
  • Caminos JE, Gualillo O, Lago F, Otero M, Blanco M, Gallego R i wsp. The endogenous growth hormone secretagogue (ghrelin) is synthesized and secreted by chondrocytes. Endocrinology 2005; 146: 1285–1292.
  • Dixit VD, Schaffer EM, Pyle RS, Collins GD, Sakthivel SK, Palaniappan R i wsp. Ghrelin inhibits leptin– and activation–induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest. 2004; 114: 57–66.
  • Konturek PC, Brzozowski T, Pajdo R, Nikiforuk A, Kwiecien S, Harsch I i wsp. Ghrelin – a new gastroprotective factor in gastric mucosa. J Physiol Pharmacol. 2004; 55: 325–336.
  • Adams CE, Greenway FL, Brantley PJ. Lifestyle factors and ghrelin: critical review and implications for weight loss maintenance. Obes Rev. 2011; 12: 211–218.
  • Couper RTL, Couper JJ. Prader Willi Syndrome Lancet 2000; 356: 673–675.
  • Kobayashi J, Kodama M, Yamazaki K, Morikawa O, Murano S, Kawamata N i wsp. Gastric bypass in a Japanese man with Prader–Willi syndrome and morbid obesity. Obes Surg. 2003; 13: 803–805.
  • Scheimann AO, Butler MG, Gourash L, Cuffari C, Klish W. Critical analysis of bariatric procedures in Prader–Willi syndrome J Pediatr Gastroenterol Nutr. 2008; 46: 80–83.
  • English PJ, Ghatei MA, Malik IA, Bloom SR, Wilding JP. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab. 2002; 87: 2984.
  • Polińska B, Matowicka–Karna J, Kemona H. Rola greliny w organizmie. Post. Hig. Med. Dosw. (online), 2011; 65: 1–7.
Document Type
paper
Publication order reference
YADDA identifier
bwmeta1.element.psjd-c54f1250-c53c-4839-86c2-64268aa63635
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.